IPA president outlines probiotic challenges

By Stephen Daniells

- Last updated on GMT

Related tags United states

Scott Bush, the VP of marketing, health and nutrition in Bioactives at Danisco USA, talks to Stephen Daniells about the challenges the probiotics industry faces in the form of new European Union health claims laws.

“We would prefer to see more detailed guidance coming from EFSA (European Food safety Authority),” ​said Bush, who is also the president of the International Probiotics Association.

He said the fact probiotic companies were in the midst of working with regulators in other jurisdictions such as Canada, the US on probiotic authentication was placing a “definite burden”​ on the industry.

Bush discusses how a plethora of probiotic strains presents challenges in conducting scientific trials and translating that science into the public domain.

Related news

Show more

Related products

show more

HRB probiotics in the HMO era

HRB probiotics in the HMO era

Content provided by Morinaga Milk Industry Co., Ltd. | 29-Apr-2024 | White Paper

Discover the science behind human-residential bifidobacteria (HRB) probiotics and their superior benefits for infants.

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 26-Apr-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Vitafoods Europe highlight: Fucoidan

Vitafoods Europe highlight: Fucoidan

Content provided by Marinova Pty Ltd | 08-Apr-2024 | Infographic

Fucoidans are bioactive compounds found naturally in brown seaweeds. Maritech® fucoidans are the world’s only high purity, certified organic fucoidans...

Related suppliers

1 comment

"detailed guidance"

Posted by frank,

“We would prefer to see more detailed guidance coming from EFSA (European Food safety Authority).”

I can give you detailed guidance: show a statistical and clinical signifcant outcome in a prospective controlled double-blinded intervention trial on an endpoint which supports the claimed effect.

Report abuse

Follow us

Products

View more

Webinars